CBT-295
Product Specifications
Target
Interleukin, TGF-beta/Smad
Related Pathways
Immunology/Inflammation, Stem Cells
Bioactivity
CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.
Molecular Formula
C18H20ClN3O
Molecular Weight
329.82
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15370408 1 Vial
Lentiviral human CALCOCO2 sgRNA gene knockout kit - Lentiviral human CALCOCO2 sgRNA gene knockout kit (100)
Sign In for Pricing
View Details 132691-ML750 100 µL
RING Finger Protein 25 (RNF25, E3 Ubiquitin-protein Ligase RNF25, AO7) (MaxLight 750) discontinued
Sign In for Pricing
View Details 